Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocvlin Plus
- Development stage
- Unknown
- Lead developer
- Jainson Biotech
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Ocvlin Plus is an ophthalmic solution developed by Jainson Biotech for the treatment of allergic eye diseases, including allergic conjunctivitis, vernal conjunctivitis, and phlyctenular conjunctivitis, as well as for the relief of eye irritation, redness, itching, congestion, and dryness. According to the manufacturer's official website, the formulation contains chlorpheniramine maleate (an antihistamine), carboxymethylcellulose (a lubricant), naphazoline (a vasoconstrictor/decongestant), and camphor (a cooling agent). However, some commercial pharmacy databases list an alternative formulation containing camphor, hydroxypropylmethylcellulose, menthol, naphazoline, and phenylephrine. The active ingredients work synergistically to reduce ocular inflammation, constrict dilated conjunctival blood vessels, block histamine-mediated allergic responses, lubricate the ocular surface, and provide a soothing, cooling sensation.
- Brand names
- Ocvlin Plus
02
Targets
ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)HRH1 (Histamine H1 Receptor)TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on Ocvlin Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocvlin Plus.